Hedgecoe Adam M
Department of Sociology, School of Social Sciences, University of Sussex, Falmer, Brighton BN1 9QN, UK.
Stud Hist Philos Biol Biomed Sci. 2006 Sep;37(3):566-82. doi: 10.1016/j.shpsc.2006.06.003. Epub 2006 Aug 23.
Most of the literature on pharmacogenetics assumes that the main problems in implementing the technology will be institutional ones (due to funding or regulation) and that although it involves genetic testing, the ethical issues involved in pharmacogenetics are different from, even less than, 'traditional' genetic testing. Very little attention has been paid to how clinicians will accept this technology, their attitudes towards it and how it will affect clinical practice. This paper presents results from interviews with clinicians who are beginning to use pharmacogenetics and explores how they view the ethics of pharmacogenetic testing, its use to exclude some patients from treatment, and how this kind of testing fits into broader debates around genetics. In particular this paper examines the attitudes of breast cancer and Alzheimer's disease specialists. The results of these interviews will be compared with the picture of pharmacogenetics painted in the published literature, as a way of rooting this somewhat speculative writing in clinical practice.
大多数关于药物遗传学的文献都认为，实施该技术的主要问题将是机构层面的问题（由于资金或监管），并且尽管它涉及基因检测，但药物遗传学中涉及的伦理问题与“传统”基因检测不同，甚至比其更少。很少有人关注临床医生将如何接受这项技术、他们对它的态度以及它将如何影响临床实践。本文展示了对开始使用药物遗传学的临床医生进行访谈的结果，并探讨了他们如何看待药物遗传学检测的伦理问题、将某些患者排除在治疗之外的做法，以及这种检测如何融入围绕遗传学的更广泛辩论。特别是，本文考察了乳腺癌和阿尔茨海默病专家的态度。这些访谈的结果将与已发表文献中描绘的药物遗传学情况进行比较，以此将这种多少有些推测性的论述扎根于临床实践之中。
